Turn Therapeutics’ (TTRX) “Sell” Rating Reaffirmed at WBB Securities

Turn Therapeutics (NASDAQ:TTRX)‘s stock had its “sell” rating restated by stock analysts at WBB Securities in a research note issued on Monday, Benzinga reports. They presently have a $10.00 price target on the stock. WBB Securities’ target price suggests a potential downside of 26.90% from the company’s previous close.

TTRX has been the subject of several other research reports. Zacks Research raised shares of Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. Wall Street Zen upgraded Turn Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. Finally, Weiss Ratings downgraded shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $9.00.

Turn Therapeutics Stock Up 7.8%

Shares of NASDAQ:TTRX traded up $0.99 during midday trading on Monday, hitting $13.68. 46,670 shares of the company’s stock traded hands, compared to its average volume of 55,069. The firm’s fifty day moving average price is $9.71 and its two-hundred day moving average price is $6.28. The company has a debt-to-equity ratio of 8.83, a quick ratio of 1.19 and a current ratio of 1.19. Turn Therapeutics has a twelve month low of $2.57 and a twelve month high of $26.50. The company has a market cap of $407.53 million and a PE ratio of -47.57.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. On average, equities research analysts anticipate that Turn Therapeutics will post -0.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Several hedge funds have recently made changes to their positions in TTRX. Hodges Capital Management Inc. acquired a new stake in Turn Therapeutics during the fourth quarter valued at approximately $39,000. LPL Financial LLC bought a new position in shares of Turn Therapeutics in the fourth quarter valued at $51,000. Bank of America Corp DE acquired a new stake in shares of Turn Therapeutics during the 2nd quarter valued at $103,000. Tamar Securities LLC acquired a new position in shares of Turn Therapeutics in the 4th quarter worth $59,000. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of Turn Therapeutics during the second quarter valued at $119,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.